Hengrui Pharma stock gains 20% by end of 2026

Market overview

Hengrui Pharma's stock will likely gain 20% by the end of 2026 as investors react to the $15B licensing deal and its long-term revenue potential. The deal validates Hengrui's R&D and commercial strategy, attracting institutional investors.

price prediction market

Implied probability (Yes)

65%

Source: user-generated

More price markets

• Bitcoin price exceeds $150,000 by end of 2026 — 68% Yes
• Bitcoin price recovers to $50,000 by December 2026 — 62% Yes
• Bitcoin price exceeds $100,000 within 6 months of Clarity Act passage — 70% Yes
• Coinbase stock to rise 15% by June 2026 amid crypto regulation clarity — 72% Yes
• NY crypto tax revenue will exceed $200M in 2027 — 65% Yes
• Will stock drop >15% on next financing terms? — 45% Yes
• Will enGene raise additional equity financing before Q1 2027? — 80% Yes
• Trading volume on Kalshi’s crypto futures exceeds $500M in first month — 60% Yes

Browse all price markets →